Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
Is there any reason to use GnRH agonists in patients with metastatic prostate cancer after bilateral orchiectomy?
Related Questions
For a patient post-prostatectomy with a high PSA (>1), a negative MRI pelvis, and a negative PSMA PET scan, do you pursue any other imaging?
How do you treat metastatic large cell neuroendocrine carcinoma of prostate with undetectable PSA, who had the treatment related transformation while on ADT monotherapy?
Under what circumstances would you treat prostate cancer without a biopsy?
How do you manage PSA progression while a patient is on xofigo or pluvicto?
For patients with oligo-progressive prostate cancer fit for metastasis-directed therapy but ineligible for radiotherapy or surgery, how do you decide between the types of ablation available?
Do you add ADT to RT for a patient with intermediate-risk prostate cancer with discordant Decipher and ArteraAI results?
For an older patient with hormone-sensitive high-volume, high-risk prostate cancer with metastases to bone who developed toxicity with enzalutamide, what other oral AR blocker would you offer?
Is there any evidence that ivermectin suppresses the PSA level in prostate cancer?
Given results of the RADICALS trials, is LT-ADT standard of care for salvage prostate RT?
What is your experience with Pylarify vs. Posluma PSMA PET for prostate cancer and is one preferred over the other?
